
FDA Reopens Comment Period on Biological Products Development Workshop
FDA Reopens Comment Period on Biological Products Development Workshop
The US Food and Drug Administration (Rockville, MD,
The objective of the workshop was to provide an opportunity for attendees to discuss the development of innovative scientific knowledge and tools to facilitate the development and availability of new biological products, including vaccines, blood and blood products, and cellular, tissue, and gene therapies (Fed. Register 70 [17], 3935 [27 January 2005]).
The notice of public workshop and request for comments was originally published in the 31 August 2004 edition of the Federal Register. At that time, the agency provided only a 23-day period for submitting comments on the workshop’s topic. The January 2006 deadline now allows interested persons additional time for submitting comments and gathering information. Electronic comments specifying Docket Number 2004N-0366 can be submitted to
Maribel Rios
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





